Restatement of Prior Financial Information (Summary of Impact of Error on Condensed Consolidated Statement of Operations) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|---|
Jun. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Mar. 31, 2023 |
Jun. 30, 2023 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||||
| Research and development | $ 8,787,636 | $ 17,860,701 | $ 20,611,127 | $ 38,471,828 | $ 47,259,464 | $ 51,202,219 | $ 70,910,701 |
| Total operating expenses | 19,690,552 | 38,506,909 | 38,156,992 | 76,663,901 | 96,354,453 | 107,071,767 | 114,079,546 |
| Operating loss | (13,736,311) | (34,414,834) | (37,454,937) | (71,869,771) | (85,606,082) | (93,782,216) | (83,488,158) |
| Loss before income taxes | (12,465,095) | (33,855,533) | (38,777,235) | (72,632,768) | (85,097,863) | (92,672,486) | (83,804,221) |
| Net loss | $ (12,522,646) | $ (33,788,974) | $ (38,708,957) | $ (72,497,931) | $ (85,020,577) | $ (93,152,692) | $ (84,040,618) |
| Net loss per basic common share outstanding | $ (0.14) | $ (0.42) | $ (0.48) | $ (0.90) | $ (1.02) | $ (1.10) | $ (1.05) |
| Net loss per diluted common share outstanding | $ (0.14) | $ (0.42) | $ (0.48) | $ (0.90) | $ (1.02) | $ (1.10) | $ (1.05) |
| As Reported [Member] | |||||||
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||||
| Research and development | $ 2,925,171 | $ 22,864,633 | $ 18,744,349 | $ 41,608,982 | $ 44,534,153 | $ 51,138,480 | $ 70,646,103 |
| Total operating expenses | 13,828,087 | 43,510,841 | 36,290,214 | 79,801,055 | 93,629,142 | 107,008,028 | 113,814,948 |
| Operating loss | (7,873,846) | (39,418,766) | (35,588,159) | (75,006,925) | (82,880,771) | (93,718,477) | (83,223,560) |
| Loss before income taxes | (6,602,630) | (38,859,465) | (36,910,457) | (75,769,922) | (82,372,552) | (92,608,747) | (83,539,623) |
| Net loss | $ (6,660,181) | $ (38,792,906) | $ (36,842,179) | $ (75,635,085) | $ (82,295,266) | $ (93,088,953) | $ (83,776,020) |
| Net loss per basic common share outstanding | $ (0.08) | $ (0.48) | $ (0.46) | $ (0.94) | $ (0.99) | $ (1.10) | $ (1.05) |
| Net loss per diluted common share outstanding | $ (0.08) | $ (0.48) | $ (0.46) | $ (0.94) | $ (0.99) | $ (1.10) | $ (1.05) |
| Adjustment [Member] | |||||||
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||||
| Research and development | $ 5,862,465 | $ (5,003,932) | $ 1,866,778 | $ (3,137,154) | $ 2,725,311 | $ 63,739 | $ 264,598 |
| Total operating expenses | 5,862,465 | (5,003,932) | 1,866,778 | (3,137,154) | 2,725,311 | 63,739 | 264,598 |
| Operating loss | (5,862,465) | 5,003,932 | (1,866,778) | 3,137,154 | (2,725,311) | (63,739) | (264,598) |
| Loss before income taxes | (5,862,465) | 5,003,932 | (1,866,778) | 3,137,154 | (2,725,311) | (63,739) | (264,598) |
| Net loss | $ (5,862,465) | $ 5,003,932 | $ (1,866,778) | $ 3,137,154 | $ (2,725,311) | $ (63,739) | $ (264,598) |
| Net loss per basic common share outstanding | $ (0.06) | $ 0.06 | $ (0.02) | $ 0.04 | $ (0.03) | ||
| Net loss per diluted common share outstanding | $ (0.06) | $ 0.06 | $ 0.04 | $ (0.03) | |||
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|